Report of the
Board of Directors

Report of the Board of Directors

The Board is pleased to present its report together with the audited consolidated financial statements of the Group for the year ended 31 December 2020.

Principal Business

Our Group is the largest distributor of pharmaceutical products, and a leading supply chain services provider in the PRC; it also operates the largest national pharmaceutical distribution network in the PRC according to the information of China Association of Pharmaceutical Commerce. The Group has been able to rapidly increase its market share and profits in a highly fragmented industry by taking advantage of its economies of scale and nationwide distribution network, through which the Group offers a wide range of value-added supply chain services for its customers and suppliers.

The Group has integrated operations in the following business segments, namely:

  • Pharmaceutical distribution segment: Pharmaceutical distribution is the Group’s principal business. The Group provides distribution, logistics and other value-added services for domestic and international pharmaceutical and healthcare products manufacturers and other suppliers. The Group differentiates itself from its competitors in China by its strengths of geographic coverage, the breadth of its product portfolio and the comprehensive supply chain services provided to its customers and suppliers, etc.
  • Medical devices segment: The Group is engaged in the distribution of medical devices in China.
  • Retail pharmacy segment: The Group has established a network of retail drug stores in major cities of China via direct operations and franchises.
  • Other business segment: The Group is also engaged in the production and sale of pharmaceutical products, chemical reagents and laboratory supplies.

Please refer to the sections headed “Management Discussion and Analysis” and “Corporate Governance Report” for a fair review and the analysis using financial key indicators on the Group’s business, major risks, subsequent events and uncertainties faced by the Group, and the future development of the Group’s business. Those sections also form a part of this Report of the Board of Directors.

Results

The operating results of the Group during the Reporting Period are set out in the consolidated statement of profit or loss on page 88 of this annual report.

Dividends

Relevant resolution was passed at a meeting of the Board held on 19 March 2021 to propose to distribute a final dividend of RMB0.69 per share (tax inclusive) for the year ended 31 December 2020 (the “Final Dividend”), totalling approximately RMB2,153,253,000. If the proposal of profit distribution is approved by Shareholders at the 2020 annual general meeting to be held on Thursday, 10 June 2021 (the “AGM”), the Final Dividend will be distributed to the Shareholders whose names appear on the register of members of the Company on Tuesday, 22 June 2021 no later than 10 August 2021.

According to the Articles of Association of the Company, the Final Dividends will be denominated and declared in Renminbi. Final Dividend on domestic shares of the Company and for investors investing in the H shares of the Company through Shanghai Hong Kong Stock Connect or Shenzhen Hong Kong Stock Connect (the “Southbound Trading”) (the “Southbound Trading Shareholders”) will be paid in Renminbi, and the Final Dividend for other holders of H shares of the Company will be paid in Hong Kong dollars. The amount of the Final Dividend payable in Hong Kong dollars shall be calculated based on the average exchange rate of Renminbi to Hong Kong dollars as announced by the People’s Bank of China for the calendar week prior to 10 June 2021 (being the date of declaration of the Final Dividend).

For the Southbound Trading Shareholders, the Company will enter into the Agreement on Distribution of Cash Dividends of H Shares for Southbound Trading (港股通H shares股票現金紅利派發協議) with China Securities Depository and Clearing Corporation Limited, pursuant to which, the Shanghai Branch and Shenzhen Branch of China Securities Depository and Clearing Corporation Limited, each of which as a nominee of the holders of H shares for Southbound Trading, will receive all the Final Dividend distributed by the Company and distribute the Final Dividend to the relevant Southbound Trading Shareholders through their depositary and clearing systems.

Pursuant to the Enterprise Income Tax Law of the PRC and its implementing regulations (hereinafter collectively referred to as the “EIT Law”), the tax rate of the enterprise income tax applicable to the income of non-resident enterprise deriving from the PRC is 10%. For this purpose, any H shares registered under the name of non-individual enterprise, including the H shares registered under the name of HKSCC Nominees Limited, other nominees or trustees, or other organizations or entities, shall be deemed as shares held by non-resident enterprise shareholders as defined under the EIT Law. The Company will distribute the Final Dividend to non-resident enterprise shareholders subject to a deduction of 10% enterprise income tax withheld and paid by the Company on their behalf.

Any resident enterprise as defined under the EIT Law which has been legally incorporated in the PRC or which has established effective administrative entities in the PRC pursuant to the laws of foreign countries (regions) and whose name appears on the register of the members of H shares of the Company should deliver a legal opinion ascertaining its status as a resident enterprise furnished by a PRC lawyer (with the official chop of the issuing law firm affixed thereon) and relevant documents to Computershare Hong Kong Investor Services Limited in due course, if they do not wish to have the 10% enterprise income tax withheld and paid on their behalf by the Company.

Pursuant to the Notice on the Issues on Levy of Individual Income Tax after the Abolishment of Guo Shui Fa [1993] No. 045 Document (the “Notice”) issued by the State Administration of Tax on 28 June 2011, the dividend to be distributed by the PRC non-foreign invested enterprises which has issued shares in Hong Kong to the overseas resident individual shareholders, is subject to the individual income tax with a tax rate of 10% in general. However, the tax rates for respective overseas resident individual shareholders may vary depending on the relevant tax agreements between the countries of their residence and Mainland China. Thus, 10% personal income tax will be withheld by the Company from the Final Dividend payable to the individual H-share shareholders whose names appear on the register of members of the Company on Tuesday, 22 June 2021, unless otherwise stated in the relevant taxation regulations, taxation agreements or the Notice. If individual H Share shareholders consider that the tax rate adopted by the Company for the withholding and payment of individual income tax on their behalf is not the same as the tax rate stipulated in any tax treaties between the PRC and the countries (regions) in which they are domiciled, after receiving the dividends, they may proceed with the subsequent tax related treatment in person or through proxy with competent tax authorities of the Company in accordance with requirements under the tax treaties.

Pursuant to the “Notice on Taxation Policies concerning the Pilot Program of an Interconnection Mechanism for Transactions in the Shanghai and Hong Kong Stock Markets” (Cai Shui [2014] No.81) (《關於滬港股票市場交易互 聯互通機制試點有關稅收政策的通知》(財稅[2014]81號)) and the “Notice on Taxation Policies concerning the Pilot Program of an Interconnection Mechanism for Transactions in the Shenzhen and Hong Kong Stock Markets” (Cai Shui [2016] No.127) (《關於深港股票市場交易互聯互通機制試點有關稅收政策的通知》(財稅[2016]127號)) jointly promulgated by the Ministry of Finance, the State Administration of Taxation and the China Securities Regulatory Commission, for dividends derived by Mainland individual investors from investing in H-share listed on the Hong Kong Stock Exchange through Shanghai Hong Kong Stock Connect or Shenzhen Hong Kong Stock Connect, H-share companies shall withhold individual income tax at a tax rate of 20% for the investors. For Mainland securities investment funds investing in shares listed on Hong Kong Stock Exchange through Shanghai Hong Kong Stock Connect or Shenzhen Hong Kong Stock Connect, the above rules also apply and individual income tax shall be levied on dividends derived therefrom. Dividends derived by Mainland enterprise investors from investing in shares listed on Hong Kong Stock Exchange through Shanghai Hong Kong Stock Connect or Shenzhen Hong Kong Stock Connect shall be reported and paid by the enterprise investors themselves. H-share companies will not withhold or pay enterprise income tax on their behalf in the distribution of dividends.

The Company will have no liability in respect of any claims arising from any delay in, or inaccurate determination of the status of the shareholders or any disputes over the mechanism of withholding.

The Board is not aware of any shareholders who have waived or agreed to waive any dividends.

Dividend Policy

The Company has established a dividend policy. Under the PRC Company Law and the Articles of Association, all of our shareholders have equal rights to dividends and distribution. The declaration of dividends by the Company will be proposed by the Board after taking into account the following factors, and is subject to the approval of the shareholders:

  1. the Company’s financial results;
  2. the Company’s shareholders’ interests;
  3. general business conditions and strategies;
  4. the Company’s capital requirements;
  5. contractual restrictions on the payment of dividends by the Company to its shareholders or by the Company’s subsidiaries to the Company;
  6. taxation considerations;
  7. possible effects on the Company’s credit worthiness;
  8. statutory and regulatory restrictions; and
  9. any other factors the Board may deem relevant.

The allocations to the statutory common reserve fund are currently determined to be 10% of the Company’s after-tax profit attributable to equity holders of the Company for the fiscal year determined in accordance with PRC accounting rules and regulations. When the accumulated allocations to the statutory common reserve fund reach 50% of the Company’s registered capital, the Company will no longer be required to make allowances for allocation to the statutory common reserve fund.

Purchase, Sale and Redemption of Listed Securities

During the Reporting Period, save as disclosed in the section headed “Restricted Share Incentive Scheme”, none of the Company and its subsidiaries had purchased, sold or redeemed any of the listed securities of the Company.

Restricted Share Incentive Scheme

The Restricted Share Incentive Scheme (the “Scheme”) of the Company took effect on 18 October 2016. According to the initial grant proposal, the restricted shares under the initial grant are subject to three unlocking periods. Since the Company failed to achieve part of the performance targets for 2019, therefore, it failed to meet unlocking conditions for the third unlocking period. Therefore, upon consideration and approval by the Board of the Company on 23 June 2020, except for certain of Scheme Participants who withdrew from the Scheme due to reasons such as resignation or change of positions, the remaining 1.8972 million restricted H shares (representing approximately 0.06% of the total issued share capital of the Company as at the date of this report and 34% of restricted H shares granted to such Scheme Participants) which have been granted to an aggregate of 153 Scheme Participants shall not be unlocked. During the Reporting Period, together with the 1.8972 million shares that will not be unlocked, the Company sold a total of 1.9468 million H Shares of the Company to the secondary market through trustee, including a small number of Shares that were sold due to certain Scheme Participants’ withdrawing from the Scheme due to resignation or change of position.

For further details of the Scheme, please refer to Note 49 to the Consolidated Financial Statements.

Principal Subsidiaries

Details of the names, principal places of business, places of incorporation and issued share capital of the Company’s principal subsidiaries are set out in Note 47 to the Consolidated Financial Statements.

Reserves

Details of movements in reserves of the Group during the Reporting Period are set out in the Consolidated Statement of Changes in Equity on page 92 of this annual report and Note 40 to the Consolidated Financial Statements.

Distributable Reserves

In accordance with the PRC Company Law, the Company may only distribute dividends out of its distributable profits of the year (i.e. the Company’s profit after tax after offsetting:

  1. the accumulated losses brought forward from the previous years; and
  2. the allocations to the statutory surplus reserve and, if any, the discretionary common reserve (in such order of priorities)).

According to the Articles of Association, for the purpose of determining distributable profit, the distributable profit of the Company shall be the lower of its profit after tax determined in accordance with: (i) the PRC accounting standards and regulations; and (ii) the HKFRSs.

In 2020, the distributable reserves of the Company, calculated based on the above principles, amounted to approximately RMB31,397 million, which is prepared in accordance with the HKFRSs.

Property, Plant, Equipment and Investment Properties

Details of changes in investment properties and property, plant and equipment of the Group during the Reporting Period are set out in Notes 17 and 18 to the Consolidated Financial Statements.

Borrowings

Details of borrowings of the Group are set out in Note 33 to the Consolidated Financial Statements.

Debenture

In order to facilitate the adjustment of the debt structure of the Group and reduce financing costs, the Group issued corporate bonds of RMB2.7 billion and super short-term commercial papers of RMB24 billion during the Reporting Period.

Details of issued bonds of the Group during the Reporting Period are set out in Note 33 to the Consolidated Financial Statements.

Use of Proceeds from Placing of H Shares

On 17 January 2020, the Company entered into the placing agreement, the terms of which were set out in the announcement of the Company dated 17 January 2020. On 23 January 2020, the Company completed the placing of 149,000,000 new H shares (“Placing Shares”) to not less than six placees, who are professional, institutional or other investors (the “H Share Placing”). The aggregate nominal value of Placing Shares was RMB149,000,000, with a nominal value of RMB1 each. The placing price of HK$27.30 per H share represented a discount of approximately 7.3% over the closing price of HK$29.45 per H share as quoted on the Hong Kong Stock Exchange on 16 January 2020 (namely the last trading date before entering into the placing agreement). The actual net proceeds from the H Share Placing amounted to HK$4,027 million, equivalent to approximately RMB3,567 million (the “Net Proceeds”) and the net price raised per H Share upon completion of the Placing was approximately HK$27.02. As stated in the announcement of the Company dated 21 August 2020, the net proceeds will be used to expand the pharmaceutical distribution, retail network and medical device business of the Company and its subsidiaries, to improve the working capital of the Company and its subsidiaries as well as to repay the interest-bearing debts of the Company.

The table below sets out the details of the use of the net proceeds from the H Share Placing as of the end of the Reporting Period:

Unit: RMB million

Use of proceeds Amount intended to be invested Amount utilised during the Reporting Period Cumulative amount invested as of the end of the Reporting Period Unutilised amount as of the end of the Reporting Period Expected utilisation timetable
Expansion of pharmaceutical distribution, retail network and medical device business of the Company and its subsidiaries 378 378 378 0 Fully utilised
Improvement of working capital of the Company and its subsidiaries 2,589 2,460 2,460 129 (Note 1) By the end of February 2021
Repayment of the interest-bearing debts of the Company 600 600 600 0 Fully utilised

Note 1: As of the date of this report, this part of proceeds has been fully used by the end of February 2021.

Major Customers and Suppliers

During the Reporting Period, purchases of goods and services from its 5 largest suppliers were less than 30% of the Group’s total purchases, and the goods and services sold to its 5 largest customers were less than 30% of the Group’s total sales.

Permitted Indemnity Provisions

The Company has maintained directors’ liability insurance to protect the Directors of the Company against any potential losses arising from his/her actual or alleged misconduct.

Connected Transactions

Pursuant to the requirements of the Listing Rules, the transactions between the Company and its connected persons (as defined under the Listing Rules) constitute connected transactions of the Company. The Company regulates and manages such transactions in compliance with the Listing Rules. The followings are the non- exempt connected transactions conducted by the Group during the Reporting Period.

Non-Exempt Continuing Connected Transactions

For the year of 2020, the Group entered into several non-exempt continuing connected transactions. The annual caps for and the actual transaction amounts of the non-exempt continuing connected transactions by the Group are set out below:

Transactions between the Group and the CNPGC Group under the Procurement Framework Agreement and Sales Framework Agreement Annual cap for the year 2020
(RMB million)
Actual Transaction
amounts for the year ended
31 December 2020
(RMB million)
Transactions between the Group and the CNPGC Group under the Procurement Framework Agreement 10,000 5,641
Transactions between the Group and the CNPGC Group under the Sales Framework Agreement 2,800 1,765

Transactions between the Group and Sinopharm Group Finance Co. under the Financial Services Framework Agreement Annual cap for the year 2020
(RMB million)
Actual Transaction
amounts for the year ended
31 December 2020
(RMB million)
Maximum daily balance of the deposits placed with Sinopharm Group Finance Co. by the Group 3,500 3,466
Interests/service fees incurred by the Group for the provision of other financial services by Sinopharm Group Finance Co. 200 108

Transaction between the Group and the CNPGC Group under the EPC General Contracting Services Framework Agreement Annual cap for the year 2020
(RMB million)
Actual Transaction
amounts for the year ended
31 December 2020
(RMB million)
Amount payable by the Group to the CNPGC Group under the EPC General Contracting Services Framework Agreement 500 23

Transaction between the Group and the Factoring Company under the Factoring Services Framework Agreement Annual cap for the year 2020
(RMB million)
Actual transaction
amounts for the year ended
31 December 2020
(RMB million)
Interests/service fees payable by the Group to the Factoring Company under the Factoring Services Framework Agreement 100 71

Transactions between the Group and the Natong Group Company under the Procurement Framework Agreement Annual cap for the year 2020
(RMB million)
Actual transaction
amounts for the year ended
31 December 2020
(RMB million)
Amount paid by the Group to the Natong Group under the Procurement Framework Agreement 1,500 924

The continuing connected transactions between the Group and the CNPGC Group under the Procurement Framework Agreement

In order to regulate the continuing connected transactions in respect of the procurement of pharmaceutical products between the Group and CNPGC Group, the Company and the CNPGC renewed the Procurement Framework Agreement of Pharmaceutical Products, Personal-care Supplies and Medical Equipment (“Procurement Framework Agreement”) on 27 October 2017, and set up the annual caps for the continuing connected transactions contemplated under the Procurement Framework Agreement for the three years ended 31 December 2020 to be RMB6,000 million, RMB8,000 million and RMB10,000 million, respectively.

Pursuant to the Listing Rules, the Procurement Framework Agreement and the annual caps for the continuing connected transactions contemplated thereunder for the three years ended 31 December 2020 have been approved by the independent shareholders of the Company.

Pursuant to the Procurement Framework Agreement, the Group has agreed to purchase pharmaceutical products, personal-care supplies and medical equipment as well as the related services from the CNPGC Group. The related services to be provided by the CNPGC Group under the Procurement Framework Agreement mainly include the transportation services, storage services, equipment maintenance and repair services, as well as other related and ancillary services.

Under the Procurement Framework Agreement, the price shall be determined in accordance with the following pricing principles: (i) The price of pharmaceutical products, personal-care supplies and medical equipment procured by the Group from the CNPGC Group under the renewed Procurement Framework Agreement will be offered by members of the CNPGC Group based on the bidding price of the relevant products, which is won by relevant member of the CNPGC Group through its participation in the public bidding process of such products conducted by the tender office of Chinese government or hospitals, deducting the gross profit of distributors at each level; (ii) where relevant members of the CNPGC Group will on a regular basis, provide the Company and its subsidiaries with the procurement price list of all types of the above-mentioned products for distributors at each level. The Company and/or its subsidiaries, after considering comprehensively a lot of factors relating to the specific product, including but not limited to the price, quality, credit period, delivery method, after-sales service, gross profit and average price in the industry and going through all necessary internal review and approval procedures covering the president and various departments including procurement department, finance department, operation department and quality department of the Company and/or its subsidiaries, will determine whether to accept the procurement price of specific product as offered by members of the CNPGC Group. If the Company and/or its subsidiaries, after taking into consideration all the above-mentioned factors, consider that the procurement price offered by members of the CNPGC Group is not in the best interest of the Company and its shareholders, or is not fair and reasonable, they will make the decision not to procure such products from the CNPGC Group.

The Procurement Framework Agreement is for a term of three years with effect from 1 January 2018 and ended on 31 December 2020. Upon expiry, the Procurement Framework Agreement will, subject to compliance with the relevant requirements under the Listing Rules and agreement of the parties, be renewed for a further term of three years. For details of the transactions, please refer to the announcement published on the websites of Hong Kong Stock Exchange and the Company on 27 October 2017.

CNPGC is the ultimate controlling shareholder of the Company and a connected person of the Company under the Listing Rules. Therefore, the transactions under the Procurement Framework Agreement between the Company and the CNPGC constitute continuing connected transactions of the Company.

As the term of the above-mentioned Procurement Framework Agreement as well as the annual caps for the continuing connected transactions thereunder expired on 31 December 2020, on 22 October 2020, the Company and CNPGC renewed the Procurement Framework Agreement for a term of three years from 1 January 2021 to 31 December 2023 (“2020 Procurement Framework Agreement”). The annual caps for the continuing connected transactions contemplated under the 2020 Procurement Framework Agreement for the three years ending 31 December 2023 amount to RMB7,000 million, RMB8,000 million and RMB9,000 million, respectively. For details of the transactions, please refer to the announcement published on the websites of Hong Kong Stock Exchange and the Company on 22 October 2020.

The continuing connected transactions between the Group and the CNPGC Group under the Sales Framework Agreement

In order to regulate the continuing connected transactions in respect of the sales of, among others, pharmaceutical products between the Group and the CNPGC Group, the Company and the CNPGC renewed the Sales Framework Agreement of Pharmaceutical Products, Personal-care Supplies, Medical Equipment, Chemical Reagents and Laboratory Supplies (“Sales Framework Agreement”) on 27 October 2017, and set up the annual caps for the continuing connected transactions contemplated under the renewed Sales Framework Agreement for the three years ended 31 December 2020 to be RMB1,400 million, RMB2,000 million and RMB2,800 million, respectively.

Pursuant to the Listing Rules, the Sales Framework Agreement and the annual caps for the continuing connected transactions contemplated thereunder for the three years ended 31 December 2020 have been approved by the Board of the Company.

Pursuant to Sales Framework Agreement, the Group has agreed to sell pharmaceutical products, personal-care supplies, medical equipment, chemical reagents and laboratory supplies as well as the related services to the CNPGC Group. The related services to be provided by the Group under the Sales Framework Agreement mainly include the transportation services, storage services, equipment maintenance and repair services, as well as other related and ancillary services.

Under the Sales Framework Agreement, the price shall be determined in accordance with the following pricing principles: (i) the price of pharmaceutical products, personal-care supplies, medical equipment, chemical reagent, chemical reagents or laboratory supplies sold by the Group to the CNPGC Group under the renewed Sales Framework Agreement will be offered by members of the Group based on the bidding price of the relevant products, which is won by relevant member of the Group through its participation in the public bidding process of such products conducted by the tender office of Chinese government or hospitals, deducting the gross profit margin of distributors at each level; (ii) the finance department of the Company will be responsible for collecting data of the continuing connected transactions conducted by itself or any of its subsidiaries on a regular basis and examining and comparing specific agreements for such continuing connected transactions with those entered into with independent third parties, so as to ensure that the pricing policies of the relevant products offered by the Company and/or its subsidiaries to the CNPGC Group are comparable to those offered to independent third parties.

The Sales Framework Agreement is for a term of three years with effect from 1 January 2018 and ended on 31 December 2020. Upon expiry, the Sales Framework Agreement will, subject to compliance with the relevant requirements under the Listing Rules and agreement of the parties, be renewed for a further term of three years. For details of the transactions, please refer to the announcement published on the websites of Hong Kong Stock Exchange and the Company on 27 October 2017.

CNPGC is the ultimate controlling shareholder of the Company and a connected person of the Company under the Listing Rules. Therefore, the transactions under the Sales Framework Agreement between the Company and the CNPGC constitute continuing connected transactions of the Company.

As the term of the above-mentioned Sales Framework Agreement as well as the annual caps for the continuing connected transactions thereunder expired on 31 December 2020, on 22 October 2020, the Company and CNPGC renewed the Sales Framework Agreement for a term of three years from 1 January 2021 to 31 December 2023 (“2020 Sales Framework Agreement”). The annual caps for the continuing connected transactions contemplated under the 2020 Sales Framework Agreement for the three years ending 31 December 2023 amount to RMB1,800 million, RMB2,000 million and RMB2,150 million, respectively. For details of the transactions, please refer to the announcement published on the websites of Hong Kong Stock Exchange and the Company on 22 October 2020.

The continuing connected transactions between the Group and Sinopharm Group Finance Co. under the Financial Services Framework Agreement

In order to regulate the continuing connected transactions in respect of the utilization of financial services between the Group and Sinopharm Group Finance Co., Ltd. (“Sinopharm Group Finance Co.”), the Company and Sinopharm Group Finance Co. renewed the Financial Services Framework Agreement (“Financial Services Framework Agreement”) on 27 October 2017, and set up the annual caps for the maximum daily balance of the deposits under the renewed Financial Services Framework Agreement for each of the three years ended 31 December 2020 to be RMB3,500 million, and the annual caps for the interests/service fees paid for the provision of other financial services under the renewed Financial Services Framework Agreement for each of the three years ended 31 December 2020 to be RMB200 million.

Pursuant to the Listing Rules, the Financial Services Framework Agreement and the annual caps for the continuing connected transactions contemplated thereunder for the three years ended 31 December 2020 have been approved by the Board of the Company.

Pursuant to the Financial Services Framework Agreement, the Company and/or its subsidiaries will, from time to time, utilize the following financial services available from Sinopharm Group Finance Co. as is deemed necessary: (i) deposit services; (ii) loan and entrustment loan services; (iii) other financial services including bill discounting and acceptance services, finance lease services, settlement services and entrustment loan agency services; and (iv) other services as approved by China Banking Regulatory Commission.

Fees and charges payable by the Company and/or its subsidiaries to Sinopharm Group Finance Co. under the Financial Services Framework Agreement are determined on the following basis:

  • deposit services: interest rates shall not be lower than each of (i) the interest rates floor promulgated by the People’s Bank of China from time to time for the same category of deposits; (ii) the interest rates offered to other members of the CNPGC Group by Sinopharm Group Finance Co. for the same category of deposits; and (iii) the interest rates offered to the Company and/or its subsidiaries by commercial banks for the same category of deposits.
  • loan services: interest rates shall not be higher than each of (i) the interest rates cap promulgated by the People’s Bank of China from time to time for the same category of loans; (ii) the interest rates offered to other members of the CNPGC Group by Sinopharm Group Finance Co. for the same category of loans; and (iii) the interest rates offered to the Company and/or its subsidiaries by commercial banks for the same category of loans.
  • other financial services: the interests or service fees charged for other financial services shall (i) comply with the standard rates as promulgated by the People’s Bank of China or China Banking Regulatory Commission from time to time (if applicable); (ii) be not higher than the interests or service fees charged by commercial banks for comparable services; and (iii) be not higher than the interests or service fees charged by Sinopharm Group Finance Co. for comparable services to other members of the CNPGC Group. Sinopharm Group Finance Co. may provide other services to the Company and/or its subsidiaries as may be approved by China Banking Regulatory Commission in the future. The fees and charges for such services to be provided shall: (i) comply with the standard rates as promulgated by the People’s Bank of China or China Banking Regulatory Commission from time to time (if applicable) for such kind of services; (ii) be not higher than the fees charged by commercial banks for comparable services; and (iii) be not higher than the fees charged by Sinopharm Group Finance Co. for comparable services to other members of the CNPGC Group.

The Financial Services Framework Agreement is effective for a term of three years from 1 January 2018 to 31 December 2020. For details of the transactions, please refer to the announcement published on the websites of Hong Kong Stock Exchange and the Company on 27 October 2017.

Sinopharm Group Finance Co. is a subsidiary of the ultimate controlling shareholder of the Company and therefore a connected person of the Company under the Listing Rules. Accordingly, the transactions under the Financial Services Framework Agreement between the Company and Sinopharm Group Finance Co. constitute continuing connected transactions of the Company.

As the term of the above-mentioned Financial Services Framework Agreement as well as the annual caps for the continuing connected transactions thereunder expired on 31 December 2020, on 18 December 2020, the Company and Sinopharm Group Finance Co. renewed the Financial Services Framework Agreement for a term of three years from 1 January 2021 to 31 December 2023 (“2020 Financial Services Framework Agreement”). The maximum daily balance of deposits under the 2020 Financial Services Framework Agreement for each of the three years ending 31 December 2023 amount to RMB2,420 million, and the annual caps for the interests/ service fees payable for the provision of other financial services under the 2020 Financial Services Framework Agreement for each of the three years ending 31 December 2023 amount to RMB500 million. For details of the transactions, please refer to the announcement published on the websites of Hong Kong Stock Exchange and the Company on 18 December 2020.

The continuing connected transactions between the Group and the CNPGC Group under the EPC General Contracting Service Framework Agreement

In order to regulate the continuing connected transactions in respect of the EPC general contracting service between the Group and the CNPGC Group, the Company and the CNPGC renewed the EPC General Contracting Service Framework Agreement (“EPC General Contracting Service Framework Agreement”) on 27 October 2017, and set up the annual caps for the continuing connected transactions contemplated under the EPC General Contracting Service Framework Agreement for each of the three years ended 31 December 2020 to be RMB500 million.

Pursuant to the Listing Rules, the EPC General Contracting Service Framework Agreement and the annual caps for the continuing connected transactions contemplated thereunder for the three years ended 31 December 2020 have been approved by the Board of the Company.

Pursuant to the EPC General Contracting Service Framework Agreement, the CNPGC Group will provide EPC (Engineering, Procurement, and Construction) general contracting services to the Group according to the engineering project general contracting agreements obtained by CNPGC Group through bidding process.

Under the EPC General Contracting Service Framework Agreement, the price shall be determined in accordance with the following pricing principles: (i) Under the EPC General Contracting Service Framework Agreement, the service provider and the price of EPC general contracting services shall be determined through a bidding process in principle and in compliance with applicable laws, regulations and rules. The CNPGC Group shall bid by stringently following the steps and/or measurements as stipulated by The Invitation And Submission of Bids Law of the PRC and the specific requirements in bidding invitation documents made by the Group; (ii) The bid invitation documents made by the Group include all substantial requirements and all key terms for the conclusion of contracts, including: the project’s technical requirements, the criteria for examination of the contractors, the requirements for the bid price and the standard of evaluation of the bid and etc. The Group’s tender committee is responsible for (i) adhering the process is in accordance with The Invitation And Submission of Bids Law of the PRC; (ii) reviewing, evaluating and monitoring documents from outsourcing service providers based on the technical, commercial and pricing criteria and payment terms of relevant service fees, which will ensure the terms obtained by the Group from the CNPGC Group is no less favorable than those available from independent third parties; and (iii) grading the service providers and writing recommendation advice. The Group’s tender committee is responsible for deciding which service provider will be awarded the EPC General Contracting Service Framework Agreement.

The EPC General Contracting Service Framework Agreement is for a term of three years with effect from 1 January 2018 and ended on 31 December 2020. Upon expiry, the EPC General Contracting Service Framework Agreement will, subject to compliance with the relevant requirements under the Listing Rules and agreement of the parties, be renewed for a further term of three years. For details of the transactions, please refer to the announcement published on the websites of Hong Kong Stock Exchange and the Company on 27 October 2017.

CNPGC is the ultimate controlling shareholder of the Company and a connected person of the Company under the Listing Rules. The transactions under the EPC General Contracting Service Framework Agreement between the Company and the CNPGC constitute continuing connected transactions of the Company.

As the term of the above-mentioned EPC General Contracting Service Framework Agreement as well as the annual caps for the continuing connected transactions thereunder expired on 31 December 2020, on 22 October 2020, the Company and CNPGC renewed the EPC General Contracting Service Framework Agreement for a term of three years from 1 January 2021 to 31 December 2023 (“2020 EPC General Contracting Service Framework Agreement”). The annual caps for the continuing connected transactions contemplated under the 2020 EPC General Contracting Service Framework Agreement for each of the three years ending 31 December 2023 amount to RMB300 million. For details of the transactions, please refer to the announcement published on the websites of Hong Kong Stock Exchange and the Company on 22 October 2020.

The continuing connected transactions between the Group and the Factoring Company under the Factoring Services Framework Agreement

In order to regulate the continuing connected transactions in respect of the factoring services between the Group and the Company and Sinopharm Puxin Commercial Factoring Company Limited (“Factoring Company”) entered into the Factoring Services Framework Agreement (“Factoring Services Framework Agreement”) on 23 March 2018, and set up the annual caps of interests/fees payable by the Group for commercial factoring services for the nine months ended 31 December 2018 and the two years ended 31 December 2020 under the Factoring Services Framework Agreement to be RMB75 million, RMB100 million and RMB100 million, respectively.

Pursuant to the Listing Rules, the Factoring Services Framework Agreement and the annual caps for the continuing connected transactions contemplated thereunder for the nine months ended 31 December 2018 and the two years ended 31 December 2020 have been approved by the Board of the Company.

Pursuant to the Factoring Services Framework Agreement, the Factoring Company will provide recourse and nonrecourse factoring and other commercial factoring services (including sales sub-account management services, accounts receivable collection services and other permitted business of the Factoring Company) to the Group.

Pursuant to the Factoring Services Framework Agreement, the comprehensive pricing (including interest and fees) of the commercial factoring services charged by the Factoring Company shall be fair and reasonable and shall not be higher than the comprehensive pricing of the same commercial factoring services provided by independent third parties to the Group during the same period.

The Factoring Services Framework Agreement shall be effective from 23 March 2018 to 31 December 2020. Upon expiry, the Factoring Service Framework Agreement will, subject to compliance with the relevant requirements under the Listing Rules and agreement of the parties, be renewed for a further term of three years. For details of the transactions, please refer to the announcement published on the websites of Hong Kong Stock Exchange and the Company on 23 March 2018.

The Factoring Company is a subsidiary of the Company’s ultimate controlling shareholder, and therefore a connected person of the Company under the Listing Rules. Accordingly, the transactions contemplated under the Factoring Services Framework Agreement constitute continuing connected transactions of the Company.

As the term of the above-mentioned Factoring Services Framework Agreement as well as the annual caps for the continuing connected transactions thereunder expired on 31 December 2020, on 22 October 2020, the Company and Factoring Company renewed the Factoring Services Framework Agreement for a term of three years from 1 January 2021 to 31 December 2023 (“2020 Factoring Services Framework Agreement”). The annual caps for the continuing connected transactions contemplated under the 2020 Factoring Services Framework Agreement for the three years ending 31 December 2023 amount to RMB150 million, RMB180 million and RMB200 million, respectively. For details of the transactions, please refer to the announcement published on the websites of Hong Kong Stock Exchange and the Company on 22 October 2020.

The continuing connected transactions between the Group and the Natong Group under the Natong Procurement Framework Agreement

In order to effectively regulate the continuing connected transactions in respect of the procurement of medical devices between the Group and Beijing Natong Technology Group Co., Ltd. (北京納通科技集團有限公司) (“Natong Group Company”), its subsidiaries and 30%-controlled companies (collectively the “Natong Group”), the Company and the Natong Group Company entered into the Procurement Framework Agreement (“Natong Procurement Framework Agreement”) for medical devices including orthopedic consumables, surgical instruments and other related or auxiliary products on 28 July 2020, and set up the annual caps for the continuing connected transactions contemplated under the Natong Procurement Framework Agreement for the three years ending 31 December 2022 to be RMB1,500 million, RMB1,800 million and RMB2,000 million, respectively.

Pursuant to the Listing Rules, the Natong Procurement Framework Agreement and the annual caps for the continuing connected transactions contemplated thereunder for the three years ending 31 December 2022 have been approved by the Board of the Company.

Pursuant to the Natong Procurement Framework Agreement, the Group has agreed to procure medical devices including orthopedic consumables, surgical instruments and other related or auxiliary products from the Natong Group, and the Natong Group has agreed to sell such products to the Group.

The Group will procure relevant products from the Natong Group on a voluntary and non-compulsory basis and is entitled to procure aforementioned products from any other third parties.

Under the Natong Procurement Framework Agreement, the price shall be determined in accordance with the following pricing principles: (i) The price of medical devices including orthopedic consumables, surgical instruments and other related or auxiliary products procured by the Group from the Natong Group under the Natong Procurement Framework Agreement will be offered by members of the Natong Group based on the bidwinning price won by members of the Natong Group in the public bidding procedures of the tender offices of Chinese government or hospitals, or the procurement price from medical institutions, deducting the gross profit of distributors at each level; (ii) The Natong Group will on a semi-annual basis, provide the Company and its subsidiaries with the procurement price list of all the specific varieties of related products of the same business type. In the event of major changes in product prices due to changes in industry policies, it will further provide the latest price list of related products in a timely manner; (iii) The Company and/or its subsidiaries, after considering comprehensively a variety of factors relating to the specific product, including but not limited to the price, quality, terms of payment, delivery method, after-sales service, gross profit and average price in the industry and going through all necessary internal review and approval procedures of the president and various departments including but not limited to business department, finance department, operation department and quality department of the Company and/or its subsidiaries, will determine whether to accept the procurement price of specific product as offered by members of the Natong Group. If the Company and/or its subsidiaries, after taking into consideration all the above-mentioned factors, consider that the procurement price offered by members of the Natong Group is not in the best interest of the Company and its shareholders, or is not fair and reasonable, they will make the decision not to procure such products from the Natong Group.

The Natong Procurement Framework Agreement is for a term from 28 July 2020 and ending on 31 December 2022. Upon expiry, the Natong Procurement Framework Agreement will, subject to compliance with the relevant requirements under the Listing Rules and agreement of the parties, be renewed for a further term of three years. For details of the transactions, please refer to the announcement published on the websites of Hong Kong Stock Exchange and the Company on 28 July 2020.

The Natong Group Company is the holding company of Beijing Natong Shichuang Investment Management Co., Ltd.(北京納通實創投資管理有限公司), a substantial shareholder of CSIMC (a significant subsidiary of the Company) and a connected person of the Company under the Listing Rules. Therefore, the transactions under the Natong Procurement Framework Agreement between the Company and the Natong Group Company constitute continuing connected transactions of the Company.

The Company has confirmed that the execution and enforcement of the implementation agreements under the continuing connected transactions set above for the year ended 31 December 2020 has followed the pricing principles of such continuing connected transactions.

The independent non-executive Directors had reviewed the above continuing connected transactions and confirmed that these transactions had been entered into:

  1. in the ordinary and usual course of business of the Group;
  2. either on normal commercial terms or on terms no less favourable to the Company; and
  3. in accordance with relevant agreements governing them on terms that are fair and reasonable and in the interests of the shareholders of the Company as a whole.

Pursuant to Rule 14A.56 of the Listing Rules, the Board engaged the auditors of the Company to perform certain agreed-upon procedures in respect of the continuing connected translations and the auditors have reported the factual findings on these procedures to the Board.

The auditors of the Company had informed the Board and confirmed that with respect to the above-mentioned continuing connected transactions, they did not:

  1. notice anything that would lead them to believe that the above-mentioned continuing connected transactions have not been approved by the Board of the Company;
  2. for the transaction involving the provision of goods or services by the Group, notice anything that would lead them to believe that the transaction was not conducted in accordance with the Group’s pricing policy in all material aspects;
  3. notice anything that would lead them to believe that the above-mentioned continuing connected transactions was not conducted in accordance with the relevant transaction agreement in all material aspects; and
  4. notice anything that would lead them believe that the above-mentioned continuing connected transactions exceeded the cap set by the Company.

Non-exempted Connected Transaction

On 6 July 2020, the Company entered into the JV Agreement with China National Biotech Group Company Limited (中國生物技術股份有限公司), Sinopharm Group Guangdong Medi-World Pharmaceutical Co., Ltd. (國藥 集團廣東環球製藥有限公司), Shanghai Shyndec Pharmaceutical Co., Ltd. (上海現代製藥股份有限公司) and China State Institute of Pharmaceutical Industry (中國醫藥工業研究總院), which are subsidiaries of CNPGC, the ultimate controlling shareholder of the Company, in relation to the formation of the Joint Venture, namely Sinopharm Smart Technology (Shanghai) Co., Ltd. (國藥智能科技(上海)有限公司) (“Sinopharm Smart Technology”). Pursuant to the JV Agreement, the Company has agreed to contribute RMB60 million in cash, representing 60% of the total capital contributions of Sinopharm Smart Technology. The board of directors of Sinopharm Smart Technology shall consist of seven directors. The Company has the right to appoint three directors. On 14 October 2020, All parties entered into a supplemental agreement (the “Supplemental Agreement”) to the JV Agreement stipulating that the number of the board of directors of Sinopharm Smart Technology is changed from seven to nine, of which the number of directors that the Company is entitled to appoint increases from three to five. Sinopharm Smart Technology was established on 6 July 2020, and became a subsidiary of the Company pursuant to the Supplemental Agreement. Please refer to the announcements published on the websites of Hong Kong Stock Exchange and the Company on 6 July 2020 and 14 October 2020 for details.

Save as disclosed above, for the year ended 31 December 2020, there is no other related party transaction or continuing related party transaction set out in Note 46 to the Consolidated Financial Statements which constitutes discloseable connected transaction or continuing connected transaction under the Listing Rules. In respect of the connected transactions and the continuing connected transactions, the Company has complied with the disclosure requirements of the Listing Rules (as amended from time to time).

Directors’ and Supervisors’ Service Contracts

Each of the Directors and Supervisors has entered into a service contract with the Company. None of the Directors and Supervisors has entered into any service contract with the Company which is not determinable by the Company within one year without payment of compensation (other than statutory compensation).

Biographies of Directors, Supervisors and Senior Management

Biographies of the Directors, Supervisors and senior management are set out from page 47 to 56 of this annual report.

The list of Directors during the Reporting Period and as at the date of this report (unless otherwise stated) is set out below:

Name Position Commencement Date Expiry Date
Executive Directors
Yu Qingming Executive Directors Re-elected on 18 September 2020 17 September 2023
Liu Yong Executive Directors Re-elected on 18 September 2020 17 September 2023
Li Zhiming (resigned) Executive Directors Re-elected on 18 September 2020 Resigned on 12 January 2021
Non-executive Directors
Chen Qiyu Non-executive Directors Re-elected on 18 September 2020 17 September 2023
Ma Ping Non-executive Directors Re-elected on 18 September 2020 17 September 2023
Hu Jianwei Non-executive Directors Re-elected on 18 September 2020 17 September 2023
Deng Jindong Non-executive Directors Re-elected on 18 September 2020 17 September 2023
Wen Deyong Non-executive Directors Re-elected on 18 September 2020 17 September 2023
Guan Xiaohui Non-executive Directors Re-elected on 18 September 2020 17 September 2023
Feng Rongli Non-executive Directors Re-elected on 18 September 2020 17 September 2023
Dai Kun (resigned) Non-executive Directors Appointed on 27 June 2019 Resigned on 29 April 2020
Independent Non-executive Directors
Zhuo Fumin Independent Non-executive Directors Re-elected on 18 September 2020 7 March 2022
Chen Fangruo Independent Non-executive Directors Re-elected on 18 September 2020 17 September 2023
Li Peiyu Independent Non-executive Directors Re-elected on 18 September 2020 17 September 2023
Wu Tak Lung Independent Non-executive Directors Re-elected on 18 September 2020 17 September 2023
Yu Weifeng Independent Non-executive Directors Re-elected on 18 September 2020 17 September 2023
Yu Tze Shan Hailson (retired) Independent Non-executive Directors Re-elected on 18 September 2020 Retired on 18 September 2020
Tan Wee Seng (retired) Independent Non-executive Directors Re-elected on 18 September 2020 Retired on 18 September 2020
Liu Zhengdong (retired) Independent Non-executive Directors Re-elected on 18 September 2020 Retired on 18 September 2020

Remunerations of Directors, Supervisors, Senior Management and Five Highest Paid Individuals

The Remuneration Committee determines and makes recommendation to the Board (as appropriate) on the remuneration and other benefits payable to the Directors. The committee regularly reviews the remuneration of all Directors to ensure that their remuneration and compensation are at appropriate level. The Group maintains competitive remuneration packages with reference to the industry standard and according to the business development of the Group, and determines remuneration of the Directors based on their qualifications, experience and contributions, to attract and retain its Directors as well as to control costs.

Details of the remuneration of the Directors and Supervisors in 2020 are set out in Note 50 to the Consolidated Financial Statements.

Details of the five highest paid individuals of the Group in 2020 are set out in Note 11 to the Consolidated Financial Statements. Details of the remuneration of the current senior management of the Company by band for the year ended 31 December 2020 are set out as follows:

Range Number of individuals
Below RMB3,000,000 2
RMB3,000,000 to RMB6,000,000 6
RMB6,000,000 to RMB9,000,000 3

Interests of Directors and Supervisors in Transaction, Arrangement or Contract

Save as the non-exempt connected transactions disclosed in this annual report, for the year ended 31 December 2020, there was no transaction, arrangement and contract of significance to which the Company, its holding company, its subsidiaries or a subsidiary of its holding company was a party and in which a Director, Supervisor or their connected entity has or had at any time during that period, in any way, whether directly or indirectly, a material interest.

Interests of Directors in Competing Business

As at 31 December 2020, none of the Directors of the Company has any interests in the competing business which would be required to be disclosed under Rule 8.10 of the Listing Rules.

Directors’, Supervisors’ and Chief Executive’s Interests and Short Positions in Shares, Underlying Shares and Debentures of the Company and Its Associated Corporations

As at 31 December 2020, the interests or short positions held by the Directors, Supervisors and Chief Executive of the Company in the shares, underlying shares and debentures of the Company or any of its associated corporations (within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “SFO”) as recorded in the register required to be kept under Section 352 of the SFO, or as otherwise notified to the Company and the Hong Kong Stock Exchange pursuant to the requirements of the Model Code are as follows:

Name Class of shares Nature of interest and the capacity Number of shares held Approximate percentage to the total number of shares of the Company
(%)
Approximate percentage to the relevant class of shares (%) Long position/short position
Yu Qingming H shares Beneficial owner 100,000 0.00 0.01 Long position
Liu Yong H shares Beneficial owner 69,300 0.00 0.01 Long position
Li Zhiming H shares Beneficial owner 85,800 0.01 0.01 Long position

Note:
The information was disclosed based on the data available on the website of the Hong Kong Stock Exchange (www. hkex.com.hk), the above-mentioned “approximate percentage to the total number of shares of the Company” is calculated based on the total number of issued shares of the Company of 3,120,656,191 as at 31 December 2020, and the “approximate percentage to the relevant class of shares” is calculated based on the total number of issued H shares of the Company of 1,341,810,740 as at 31 December 2020.

Save as disclosed above, as at 31 December 2020, none of the Directors, Supervisors and the chief executive of the Company had any interests or short positions in the shares, underlying shares and debentures of the Company or any of its associated corporations (within the meaning of Part XV of the SFO) as recorded in the register required to be kept under Section 352 of the SFO, or as otherwise notified to the Company and the Hong Kong Stock Exchange pursuant to the requirements of the Model Code.

Rights to Purchase Shares or Debentures of Directors, Supervisors and Chief Executive

No arrangements to which the Company, any of its subsidiaries, its holding company or any subsidiary of its holding company is or was a party enabling the Directors, Supervisors and the chief executive of the Company to acquire benefits by means of acquisitions of shares or debentures of the Company or any other body corporate subsisted during the Reporting Period.

Substantial Shareholders’ Interests and Short Positions in Shares and Underlying Shares of the Company

As at 31 December 2020, to the best knowledge of the Directors, the interests or short positions of the following persons (other than the Directors, Supervisors or the chief executive of the Company) in the shares and underlying shares of the Company as recorded in the register required to be kept under section 336 of the SFO are as follows:

Name Class of shares Nature of interest and capacity shares held shares held Approximate percentage to the total number of shares of the Company
(%)
Approximate percentage to the relevant class of shares
(%)
Long position/short position
CNPGC Domestic shares Beneficial owner 207,289,498
(Note 2)
6.64 11.65 Long position
Domestic shares Interest of controlled corporation 1,571,555,953
(Notes 1 and 2)
50.36 88.35 Long position
Sinopharm Investment Domestic shares Beneficial owner 1,571,555,953
(Notes 1 and 2)
50.36 88.35 Long position
Fosun Pharma Domestic shares Interest of controlled corporation 1,571,555,953
(Notes 1 and 3)
50.36 88.35 Long position
Fosun High Technology Domestic shares Interest of controlled corporation 1,571,555,953
(Notes 1 and 4)
50.36 88.35 Long position
Fosun International Domestic shares Interest of controlled corporation 1,571,555,953
(Notes 1 and 5)
50.36 88.35 Long position
Fosun Holdings Domestic shares Interest of controlled corporation 1,571,555,953
(Notes 1 and 6)
50.36 88.35 Long position
Fosun International Holdings Domestic shares Interest of controlled corporation 1,571,555,953
(Notes 1 and 7)
50.36 88.35 Long position
Mr. Guo Guangchang Domestic shares Interest of controlled corporation 1,571,555,953
(Notes 1 and 8)
50.36 88.35 Long position
Citigroup Inc. H shares Interest of controlled corporation 5,812,009 0.19 0.43 Long position
3,786,095 0.12 0.28 Short position
Approved lending agent (Note 9) 86,521,061 2.77 6.44 Long position

Notes:

The information was disclosed based on the data available on the website of the Hong Kong Stock Exchange (www. hkexnews.hk).

  1. Such 1,571,555,953 domestic shares belong to the same batch of shares.
  2. CNPGC is interested in 207,289,498 domestic shares directly and 1,571,555,953 domestic shares indirectly through Sinopharm Investment. As CNPGC owns 51% equity interest in Sinopharm Investment, it is deemed to be interested in the shares held by Sinopharm Investment for the purposes of the SFO.
  3. Fosun Pharma is the beneficial owner of 49% equity interest in Sinopharm Investment and, therefore, Fosun Pharma is deemed to be interested in the domestic shares owned by Sinopharm Investment for the purposes of the SFO.
  4. Fosun High Technology is the beneficial owner of 38.62% equity interest in Fosun Pharma and, therefore, Fosun High Technology is deemed to be interested in the domestic shares owned by Sinopharm Investment for the purposes of the SFO.
  5. Fosun International is the beneficial owner of 100% equity interest in Fosun High Technology and, therefore, Fosun International is deemed to be interested in the domestic shares owned by Sinopharm Investment for the purposes of the SFO.
  6. Fosun Holdings is the beneficial owner of 71.74% equity interest in Fosun International and, therefore, Fosun Holdings is deemed to be interested in the domestic shares owned by Sinopharm Investment for the purposes of the SFO.
  7. Fosun International Holdings Ltd. (“Fosun International Holdings”) is the beneficial owner of 100% equity interest in Fosun Holdings and, therefore, Fosun International Holdings is deemed to be interested in the domestic shares owned by Sinopharm Investment for the purposes of the SFO.
  8. Mr. Guo Guangchang is the beneficial owner of 85.29% equity interest in Fosun International Holdings and 0.004% equity interest in Fosun Pharma and, therefore, Mr. Guo Guangchang is deemed to be interested in the domestic shares owned by Sinopharm Investment for the purposes of the SFO.
  9. Citigroup Inc. is interested in 92,333,070 H Shares of the Company in an aggregate in long position (including 86,521,061 H Shares available for lending) in long position and 3,786,095 H Shares in short position.
  10. The above-mentioned “approximate percentage to the total number of shares of the Company” is calculated based on the 3,120,656,191 total number of issued shares of the Company as at 31 December 2020. For H shares, the term of “approximate percentage to the relevant class of shares” is calculated based on the total number of issued H shares of the Company of 1,341,810,740 as at 31 December 2020. For domestic shares, the term of “approximate percentage to the relevant class of shares” is calculated based on the total number of issued domestic shares of the Company of 1,778,845,451 as at 31 December 2020.

Save as disclosed above, to the best knowledge of the Directors, as at 31 December 2020, no person (other than the Directors, Supervisors or the chief executive of the Company) had any interests or short positions in the shares or underlying shares of the Company as recorded in the register required to be kept under section 336 of the SFO.

Pre-Emptive Rights

There are no provisions for pre-emptive rights under the Articles of Association and the laws of the PRC which oblige the Company to offer pre-emptive rights of new shares to existing shareholders on their shareholding proportion.

Sufficiency of Public Float

Based on the information that is publicly available to the Company and to the best knowledge of the Directors, there was sufficient public float of more than 25% of the Company’s issued shares as required under the Listing Rules during the year of 2020 and as at the latest practicable date prior to the issue of this annual report.

Management Contract

There was no contract concerning the management or administration of the whole or any substantial part of the business of the Company which was entered into or existed during the Reporting Period.

Pension Scheme

During the Reporting Period, details of the pension scheme of the Group are set out in Note 37 to the Consolidated Financial Statements.

Donation

During the Reporting Period, details of the donation of the Group are set out in Note 9 to the Consolidated Financial Statements.

Environmental Policy and Performance

In accordance with the Environmental Protection Law of the People’s Republic of China and the Energy Conservation Law of the People’s Republic of China, the Company actively carries out the state policies and guidelines on energy conservation and ecological environmental protection, strictly implements state laws, regulations, standards and codes on energy conservation and environmental protection, earnestly fulfills the annual objective of energy conservation and environmental protection, carries out various tasks of energy conservation and environmental protection firmly and effectively, spares no effort to do a good job of environmental risk control, intensifies potential hazard investigation and control, effectively controls the discharge of main pollutants and saves energy resources, facilitates enterprises to seek sustainable efficient development, insists on the principle of “putting prevention first and integrating prevention and treatment”, and advocates clean production, resource recycling and energy conservation, so as to prevent or reduce the generation of pollutants at the source.

The Company has formulated the Letter of Responsibility for Energy Conservation and Environmental Protection Targets, Rules for Implementation of Sinopharm Concerning Environmental Protection and Energy Conservation and Emission Reduction Management, Administrative Measures for Hazardous Wastes and other management systems, which cover a number of energy conservation and environmental protection requirements in terms of environmental protection management, environmental contingency plans and drills, management of hazardous wastes, clean production review and energy audit, clarifying the responsibilities of environmental protection management and energy conservation and emission reduction that personnel at all levels should bear and enhancing environmental protection consciousness of all the companies. The person in charge shall be the first person responsible for the environmental protection of each subsidiary. The performance shall be included into the annual assessment of the person in charge of such subsidiary in order to improve the responsibility awareness for environmental protection of enterprise leaders. The responsible person of each subsidiary shall take the overall responsibility for environmental protection and achieve target-oriented responsibility system management.

Entrusted Deposit and Matured Time Deposit

As at 31 December 2020, the Company had not held any deposits under trust or any time deposit in any financial institution in the PRC which could not be withdrawn upon maturity.

Tax Relief and Exemption

Save as disclosed in this annual report, the Company is not aware that any holders of securities of the Company are entitled to any tax relief or exemption by reason of their holding of such securities.

Confirmation of Independence by Independent Non-executive Directors

The Company had received annual confirmation of independence from each of the independent non-executive Directors. Based on the confirmation, the Company considers that all independent non-executive Directors are independent under the Listing Rules.

Auditor

The financial statements set out in this annual report have been audited by Ernst & Young.

By Order of the Board
Sinopharm Group Co. Ltd.
Yu Qingming
Chairman

Shanghai, the PRC
19 March 2021

EN
Top